These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6196450)

  • 21. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients.
    Bash JA; Teitelbaum D; Sreevalsan T; Neefe JR
    J Biol Response Mod; 1983; 2(1):57-65. PubMed ID: 6606019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon.
    Eriksson B; Oberg K; Alm G; Karlsson A; Lundqvist G; Magnusson A; Wide L; Wilander E
    Cancer Treat Rep; 1987 Jan; 71(1):31-7. PubMed ID: 2878718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of multiple myeloma with recombinant human leukocyte A interferon.
    Ohno R; Kimura K; Amaki I; Imamura Y; Masaoka T; Miyazaki T; Yoshida Y; Miura Y; Maekawa T; Oguro M
    Cancer Treat Rep; 1985 Dec; 69(12):1433-5. PubMed ID: 4075317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of non-hodgkin's lymphoma of low-grade malignancy with human fibroblast interferon.
    Siegert W; Theml H; Fink U; Emmerich B; Kaudewitz P; Huhn D; Böning L; Abb J; Joester KE; Bartl R; Riethmüller G; Wilmanns W
    Anticancer Res; 1982; 2(4):193-8. PubMed ID: 7149647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].
    Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Schwarzenberg L; Machover D; Ribaud P; de Vassal F
    Biomed Pharmacother; 1982 Mar; 36(2):112-6. PubMed ID: 7126777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I pharmacotoxicology study of human fibroblast interferon in human cancers.
    McPherson TA; Tan YH
    J Natl Cancer Inst; 1980 Jul; 65(1):75-9. PubMed ID: 6156261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase I study of recombinant human interferon alpha A (Ro 22-8181) in patients with malignant tumors].
    Taguchi T
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):456-64. PubMed ID: 4004281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma.
    Sarna GP; Figlin RA; Pertcheck M
    J Biol Response Mod; 1987 Aug; 6(4):375-8. PubMed ID: 3625229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
    Sarna G; Figlin R; Callaghan M
    J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.
    Harris J; Das Gupta T; Vogelzang N; Badrinath K; Bonomi P; Desser R; Locker G; Blough R; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):293-4. PubMed ID: 3948193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferons and cancer therapy.
    Priestman TJ
    J Pathol; 1983 Nov; 141(3):287-95. PubMed ID: 6363649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
    Kimura K
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical experience with alpha and beta interferon in childhood cancer].
    Ise T; Ohira M; Takayama J; Hanada M; Muchi H; Fukuma H; Beppu Y; Nomura K
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1855-62. PubMed ID: 6591860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.
    Budd GT; Bukowski RM; Miketo L; Yen-Lieberman B; Proffitt MR
    Cancer Chemother Pharmacol; 1984; 12(1):39-42. PubMed ID: 6690072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.